Hakkımızda İletişim Etkileşimler: 118 620
Ada göre bir ilaç arayın

Aspirin, butalbital, caffeine, and codeine ve Karaciğer hastalığı

Aspirin, butalbital, caffeine, and codeine ilacının Karaciğer hastalığı hastalığı ile etkileşiminin güvenlik kontrolünün sonucu.

Kontrolün sonucu:
Aspirin, butalbital, caffeine, and codeine <> Karaciğer hastalığı
Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Genel olarak, CNS uyarıcılar yaygın olarak karaciğer tarafından metabolize edilir. Plazma klerensi azalmış olabilir ve half-life onların böbrek fonksiyonu bozulmuş olan hastalarda uzun süreli. CNS uyarıcılar ile tedavi dikkatli hastalarda orta ve şiddetli karaciğer hastalığı ile uygulanmalıdır ve doz buna göre ayarlanmalıdır. Ayrıca, pazarlama sonrası raporlarda, davranışsal şiddetli karaciğer yaralanmalara neden olabilir göstermiştir. Laboratuvar test (sarılık, koyu renkli idrar, üst kadranda hassasiyet) karaciğer fonksiyon bozukluğu ilk işaret ya da semptom yapılmalıdır ve tedavi karaciğer hasarı olan hastalarda kesilmelidir.

Kaynaklar
  • "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.
Aspirin, butalbital, caffeine, and codeine

Jenerik adı: aspirin / butalbital / caffeine / codeine

Marka adı: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Eşdeğer ilaçlar: Butalbital, Aspirin, Caffeine, and Codeine

Aspirin, butalbital, caffeine, and codeine nedir?
Diğer ilaç Sil
Aspirin, butalbital, caffeine, and codeine <> Karaciğer hastalığı
Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Narkotik (opioid) analjezik ajanlar yaygın olarak karaciğer tarafından metabolize edilir, ve (örneğin, kodein, hydrocodone, meperidin, metadon, morfin, menstrual onlardan çok daha fazla etkin olmayan maddelere dönüştürülmüş aktif metabolitleri vardır. Bu ajanlar ve metabolitleri serum konsantrasyonu artabilir ve yarım böbrek fonksiyonu bozulmuş olan hastalarda uzun süreli yaşıyor. Opioid ile tedavi dikkatle ve azaltılmış dozlarda karaciğer hastalığı olan hastalarda uygulanan ve başlanmalıdır. Sonraki dozlar oldukça sabit bir dozaj program daha bireysel yanıta bağlı titre edilmelidir.

Kaynaklar
  • "Product Information. Kadian (morphine)." Zeneca Pharmaceuticals, Wilmington, DE.
  • "Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories, Nutley, NJ.
  • "Product Information. Nubain (nalbuphine)." Endo Laboratories, Texarkana, TX.
  • "Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company, Vernon Hills, IL.
  • "Product Information. Sufenta (sufentanil)." Janssen Pharmaceutica, Titusville, NJ.
  • Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992): 467-74
  • "Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company, Whippany, NJ.
  • Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991): 635-42
  • McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980): 106-14
  • "Product Information. Calcidrine (codeine)." Abbott Pharmaceutical, Abbott Park, IL.
  • Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989): 463-9
  • Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982): 1267-70
  • Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978): 488-93
  • "Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  • "Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company, Whippany, NJ.
  • "Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  • Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996): 812-20
  • Gram LF, Schou J, Way WL, et al "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979): 473-82
  • "Product Information. Numorphan (oxymorphone)" Endo Laboratories LLC, Chadds Ford, PA.
  • Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990): 289-97
  • "Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceutical, Richmond, VA.
  • Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979): 96-102
  • Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992): 487-95
  • Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993): 463-72
  • Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991): 1-23
  • "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.
  • "Product Information. Dolophine (methadone)." Lilly, Eli and Company, Indianapolis, IN.
  • "Product Information. OxyContin (oxycodone)." Purdue Frederick Company, Norwalk, CT.
  • Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995): 619-23
  • Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979): 314-7
  • McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974): 281-7
  • Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983): 3-17
  • "Product Information. MS Contin (morphine)." Purdue Frederick Company, Norwalk, CT.
  • Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984): 73-7
  • Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968): 754-62
  • "Product Information. Opium Tincture (opium)" Lilly, Eli and Company, Indianapolis, IN.
  • Pond SM, Tong T, Benowitz NL, et al "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981): 183-8
  • Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993): 344-54
  • "Product Information. Darvon (propoxyphene)." Lilly, Eli and Company, Indianapolis, IN.
  • Novick DM, Kreek MJ, Arns PA, et al "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985): 349
  • "Product Information. Alfenta (alfentanil)." Janssen Pharmaceutica, Titusville, NJ.
  • Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980): 417-24
  • Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987): 293-8
  • "Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.
  • "Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc), Canonsburg, PA.
  • Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992): 479-84
  • Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990): 12-9
  • Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993): 893-903
  • Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992): 617-21
  • Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991): 381-90
  • Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972): 244
  • Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995): 37-44
  • Kreek MJ, Fanizza AM, et al "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981): 353-62
  • Parab PV, Ritschel WA, Coyle DE, et al "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988): 187-99
  • Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991): 330-6
  • Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991): 516-8
  • Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992): 462-5
  • "Product Information. Dalgan (dezocine)." Astra USA, Westborough, MA.
Aspirin, butalbital, caffeine, and codeine

Jenerik adı: aspirin / butalbital / caffeine / codeine

Marka adı: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Eşdeğer ilaçlar: Butalbital, Aspirin, Caffeine, and Codeine

Aspirin, butalbital, caffeine, and codeine nedir?
Diğer ilaç Sil
Aspirin, butalbital, caffeine, and codeine <> Karaciğer hastalığı
Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Barbitüratlar yoğun olarak karaciğer tarafından metabolize edilir. Barbitüratlar plazma klerensi azalabilir ve yarım böbrek fonksiyonu bozulmuş olan hastalarda uzun süreli yaşıyor. Barbitüratlar ile tedavi dikkatle azaltılmış dozlarda karaciğer hastalığı olan hastalarda uygulanan ve başlanmalıdır. Barbitüratlar siroz, karaciğer yetmezliği, hepatik koma veya diğer şiddetli karaciğer yetmezliği olan hastalarda kullanım için önerilmez.

Kaynaklar
  • "Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company, Indianapolis, IN.
  • Kallberg N, Agurell S, Ericsson O, et al "Quantitation of phenobarbital and its main metabolites in human urine." Eur J Clin Pharmacol 9 (1975): 161-8
  • "Product Information. Amytal Sodium (amobarbital)" Lilly, Eli and Company, Indianapolis, IN.
  • Whyte MP, Dekaban "Metabolic fate of phenobarbital: a quantitative study of p-hydroxyphenobarbital elimination in man." Drug Metab Dispos 5 (1977): 63-9
  • "Product Information. Mebaral (mephobarbital)" Sanofi Winthrop Pharmaceuticals, New York, NY.
  • "Product Information. Butisol Sodium (butabarbital)" Wallace Laboratories, Cranbury, NJ.
  • "Product Information. Nembutal Sodium (pentobarbital)" Abbott Pharmaceutical, Abbott Park, IL.
  • "Product Information. Seconal Sodium (secobarbital)" Lilly, Eli and Company, Indianapolis, IN.
  • Alvin J, McHorse T, Hoyumpa A, et al "The effect of liver disease in man on the disposition of phenobarbital." J Pharmacol Exp Ther 192 (1975): 224-35
Aspirin, butalbital, caffeine, and codeine

Jenerik adı: aspirin / butalbital / caffeine / codeine

Marka adı: Ascomp with Codeine, Fiorinal with Codeine, Fiortal with Codeine, Ascomp-Codeine, Fiorinal/Codeine #3

Eşdeğer ilaçlar: Butalbital, Aspirin, Caffeine, and Codeine

Aspirin, butalbital, caffeine, and codeine nedir?
Diğer ilaç Sil
Yaygın etkileşimlerin listesi
DiseDoc Dünya
Gıda ve yaşam tarzı ile etkileşim
  1. Aspirin, butalbital, caffeine, and codeine
Ilaç etkileşimlerini
  1. Aspirin, butalbital, caffeine, and codeine
Hizmetlerimizi iyileştirmek için çerezleri kullanırız. Devam ediyorsanız çerezlerin kullanılmasını kabul ediyorsunuz. Tamam